Clinical Implications and Unmet Needs in CLL BTKi Therapies

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Tara Graff, DO

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi) trials in chronic lymphocytic leukemia (CLL) are addressing unmet needs by offering new treatment options that target treatment-naive patients, potentially improving outcomes and filling gaps in the current therapeutic landscape.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

Now Viewing

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

Video content above is prompted by the following:

What are the clinical implications of these trials, and which unmet needs are being addressed or potentially fulfilled in the CLL landscape?